| 804.62 -16.57 (-2.02%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1054.87  |
1-year : | 1128.4 |
| Resists | First : | 903.14 |
Second : | 966.09 |
| Pivot price | 893.78 |
|||
| Supports | First : | 801.29 |
Second : | 666.68 |
| MAs | MA(5) : | 845.98 |
MA(20) : | 897.29 |
| MA(100) : | 812.5  |
MA(250) : | 685.85 |
|
| MACD | MACD : | -10.3 |
Signal : | 4.9 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 17.9 |
| RSI | RSI(14): 31.2 |
|||
| 52-week | High : | 966.09 | Low : | 446.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LLY ] has closed above bottom band by 2.6%. Bollinger Bands are 174.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 823.74 - 828.69 | 828.69 - 832.37 |
| Low: | 789.52 - 796.06 | 796.06 - 800.92 |
| Close: | 796.07 - 805.68 | 805.68 - 812.83 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Fri, 26 Jul 2024
Eli Lilly and Company (NYSE:LLY) Stock Price Down 0.9% - MarketBeat
Fri, 26 Jul 2024
Is Eli Lilly's Stock in a Bubble? - Yahoo Finance
Fri, 26 Jul 2024
Is Eli Lilly Stock A Sell On A Second Stumble In Obesity Treatment? - Investor's Business Daily
Fri, 26 Jul 2024
Prediction: This Is What Eli Lilly Stock Will Do Next - The Motley Fool
Fri, 26 Jul 2024
Is Eli Lilly Stock Headed Toward $1300 Levels? - Forbes
Thu, 25 Jul 2024
Why Eli Lilly and Company Shares Are Moving Lower On Thursday - Eli Lilly and Co (NYSE:LLY) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 900 (M) |
| Shares Float | 898 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 83.6 (%) |
| Shares Short | 5,990 (K) |
| Shares Short P.Month | 6,160 (K) |
| EPS | 6.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.22 |
| Profit Margin | 17 % |
| Operating Margin | 31.2 % |
| Return on Assets (ttm) | 12.6 % |
| Return on Equity (ttm) | 50.7 % |
| Qtrly Rev. Growth | 26 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 39.9 |
| EBITDA (p.s.) | 14.84 |
| Qtrly Earnings Growth | 66.4 % |
| Operating Cash Flow | 3,680 (M) |
| Levered Free Cash Flow | -1,230 (M) |
| PE Ratio | 118.85 |
| PEG Ratio | 0.9 |
| Price to Book value | 56.54 |
| Price to Sales | 20.16 |
| Price to Cash Flow | 196.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|